FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

British Journal of Cancer

Volumn 94, Issue 6, 2006, Pages 798-805

  Souglakos, J ^a   Androulakis, N ^a   Syrigos, K ^b   Polyzos, A ^c   Ziras, N ^d   Athanasiadis, A ^e   Kakolyris, S ^f   Tsousis, S ^g   Kouroussis, Ch ^h   Vamvakas, L ^a   Kalykaki, A ^a   Samonis, G ^a   Mavroudis, D ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d 'METAXA'S' Anticancer Hospital of Athens   (Greece)

^e GENERAL HOSPITAL OF LARISSA   (Greece)

^f DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^g Venizelion General Hospital   (Greece)

^h THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Colorectal cancer; FOLFOXIRI; Metastatic

Indexed keywords

ATROPINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DYSESTHESIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUROSENSORY TOXICITY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645309877     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603011     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2005 http://www.cancer.org/downloads/STT/CAFF2005f4PWsecured. pdf. Assessed March 8, 2005
2. Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4): 1-3
3. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050
4. Cox DR (1972) Regression models and life-tables. J R Stat Soc 34B: 187-220
5. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leukovorin and fluorouracil bolus with bimonthly high dose leukovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 14: 808-815
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041-1047
8. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20: 4006-4014
9. Ferlay J, Bray F, Sankila R (1999) Cancer Incidence, Mortality and Prevalence in the European Union. IARC Press: Lyon
10. Fischel JL, Rostagno P, Etienne MC (1999) Optimal combination between irinotecan (CPT-11), oxaliplatin (L-OHP) and fluorouracil-folinic acid (FUFOL): experimental data on human colorectal cell lines. Proc Am Assoc Cancer Res 40: 589 (abstract 3882)
11. Freedman LS (1982) Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1: 121-129
12. Goldberg R, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
13. Grothey AA, Sargent D, Goldberg R, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214
14. Hsiang YH, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA clevable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
15. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann of Oncol 13: 308-317
17. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ (1998) Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as a weekly 24-h infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncl 16: 418-426
18. National Cancer Institute (1999) Common Toxicity Criteria, version 2.0
19. O'Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35: 549-556
20. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
21. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31: 103-115
22. Poon MA, O'Connel MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418
23. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053-1071
24. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865
25. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
26. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Diaz-Rubio E (2005) Irinotecan in combination with fluorouracil in a 48-h continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the treatment of digestive tumors study. J Clin Oncol 23: 3545-3551
27. Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V (2002) A triplet combination with irinotecan (cpt-11) plus oxaliplatin (1-ohp) plus continuous infusion 5-fluorouracil (5-fu) and leucovorin (lv) as first line treatment in metastatic colorectal cancer (MCC): a multicenter phase II trial. J Clin Oncol 20: 2661-2667
28. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis CH, Agelaki S, Xenidis N, Milaki G, Georgoulias V (2005) Combination of irinotecan (CPT-11) plus bolus followed by continuous infusion 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI) as first line treatment for elderly patients with metastatic colorectal cancer (MCC): A phase II trial. Oncology 69: 384-390
29. Tanizawa A, Fujimori A, Fujimori Y, Pmmier Y (1994) Comparision of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothesin derivates presently in clinical trials. J Natl Cancer Inst 86: 836-842
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
31. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22: 229-237
32. Wadler S, Benson III AB, Engelkinget C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16: 3169-3178